Life science venture capital firm RiverVest Venture Partners is adding a new position to its roster, naming Bradley Keller as the firm’s first Entrepreneur-in-Residence (EIR). Keller, who has more than 20 years of experience in drug discover and development, will help the firm identify and evaluate potential funding opportunities in the pharmaceutical and biotechnology space, according to a statement. Keller ...

By Deena Beasley LOS ANGELES (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc and AstraZeneca have grown dependent on higher U.S. prices to generate profits as generic rivals to their best-selling medicines enter the world market, ...

Pain Therapeutics Inc. (NASDAQ: PTIE) dipped 45.01% to $5.32 in the pre-market session after the company CEO revealed a letter from Pfizer (NYSE: PFE) of reassessing its endorsement of the Remoxy program. Santarus, Inc.

Josh Bloom recently wrote a very provocative piece entitled: “How can Merck look itself in the mirror?” Bloom is concerned that this once greatly admired pharmaceutical company has lost its way by bringing to market the LDL cholesterol lowering drug, Liptruzet. Liptruzet is actually the combination of two drugs that are already on the market: its own Zetia (generic name: ...

Federal authorities in Puerto Rico have arrested an executive at Pfizer Pharmaceutical for allegedly producing child pornography.